Charles Hauswald is a senior life sciences advisor with deep expertise in strategic consulting, scientific and commercial due diligence, and operational value creation across the pharmaceutical, biotechnology, and medical technology sectors. He advises private equity and venture capital firms, as well as executive leadership teams, on evaluating investment opportunities, mitigating risk, and accelerating growth across the product lifecycle.

Mr. Hauswald brings extensive experience in drug development strategy, quality and regulatory frameworks, and outsourced development and manufacturing models (CDMO/CRO). He has supported numerous transactions through rigorous diligence processes and post-investment value creation initiatives, with a focus on optimizing development pathways, strengthening operational performance, and enhancing regulatory readiness.

He is recognized for his ability to integrate scientific, regulatory, and commercial perspectives into clear, actionable strategies that drive informed decision-making at the board and investor level. His work spans early-stage innovation through commercialization, with a strong track record of supporting successful investment outcomes.